PromaCare-TA / Tranexamic Acid

Short Description:

PromaCare-TA is a generic drug,essential antifibrinolytic agent in WHO list. It has been used as a traditional hemostatic medicine.It is a drug for the inhibition of plasminogen to plasmin in blood. Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.

Product Detail

Product Tags


Trade name PromaCare-TA
CAS 1197-18-8
Product Name Tranexamic Acid
Chemical Structure
Application Medicine
Package 25kgs net per drum
Appearance White or almost white, crystalline power
Assay 99.0-101.0%
Solubility Water soluble
Shelf life 4 years
Storage Keep container tightly closed and in a cool place. Keep away from heat.


Tranexamic Acid, also known as clotting acid, is an antifibrinolytic amino acid, which is one of the commonly used anticoagulants in clinic

This product can be used for:

1. Trauma or surgical bleeding of prostate, urethra, lung, brain, uterus, adrenal gland, thyroid, liver and other organs rich in plasminogen activator.

2. They are used as thrombolytic agents, such as tissue plasminogen activator (t-PA), streptokinase and urokinase antagonist.

3. Induced abortion, placental exfoliation, stillbirth and amniotic fluid embolism caused by fibrinolytic bleeding.

4. Menorrhagia, anterior chamber hemorrhage and severe epistaxis with increased local fibrinolysis.

5. It is used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophilic patients with factor VIII or factor IX deficiency.

6. This product is superior to other antifibrinolytic drugs in hemostasis of mild hemorrhage caused by rupture of central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage. However, attention must be paid to the risk of cerebral edema or cerebral infarction. As for severe patients with surgical indications, this product can only be used as an adjuvant.

7. For the treatment of hereditary vascular edema, can reduce the number of attacks and severity.

8. Patients with hemophilia have active bleeding.

9. It has definite curative effect on chloasma.

  • Previous:
  • Next: